Virtus ETF Advisers LLC Sells 1,135 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)

Virtus ETF Advisers LLC reduced its stake in Denali Therapeutics Inc. (NASDAQ:DNLI) by 27.3% during the fourth quarter, HoldingsChannel.com reports. The fund owned 3,029 shares of the company’s stock after selling 1,135 shares during the quarter. Virtus ETF Advisers LLC’s holdings in Denali Therapeutics were worth $62,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of DNLI. Norges Bank bought a new stake in Denali Therapeutics in the 4th quarter valued at $21,717,000. Vanguard Group Inc. increased its holdings in Denali Therapeutics by 7.6% in the 4th quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company’s stock valued at $244,993,000 after acquiring an additional 843,996 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Denali Therapeutics by 19.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,855,036 shares of the company’s stock valued at $37,805,000 after buying an additional 295,594 shares in the last quarter. Segall Bryant & Hamill LLC bought a new position in shares of Denali Therapeutics in the 4th quarter valued at about $5,891,000. Finally, Alliancebernstein L.P. grew its position in Denali Therapeutics by 8.8% in the fourth quarter. Alliancebernstein L.P. now owns 3,315,642 shares of the company’s stock worth $67,573,000 after acquiring an additional 268,378 shares in the last quarter. 92.92% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on DNLI. Robert W. Baird began coverage on Denali Therapeutics in a research note on Tuesday, January 7th. They issued an “outperform” rating and a $31.00 price objective for the company. HC Wainwright lifted their target price on Denali Therapeutics from $80.00 to $87.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Deutsche Bank Aktiengesellschaft began coverage on Denali Therapeutics in a report on Tuesday, February 11th. They issued a “buy” rating and a $31.00 target price for the company. The Goldman Sachs Group dropped their target price on Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a report on Tuesday, January 28th. Finally, Morgan Stanley began coverage on Denali Therapeutics in a report on Friday, March 7th. They issued an “overweight” rating and a $33.00 target price for the company. One research analyst has rated the stock with a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Denali Therapeutics presently has a consensus rating of “Buy” and an average price target of $37.57.

Denali Therapeutics Stock Up 3.6 %

Shares of NASDAQ DNLI opened at $16.25 on Tuesday. The business has a fifty day simple moving average of $14.85 and a two-hundred day simple moving average of $20.71. The firm has a market cap of $2.36 billion, a PE ratio of -5.89 and a beta of 1.58. Denali Therapeutics Inc. has a twelve month low of $10.57 and a twelve month high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.08. On average, research analysts expect that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.